Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. (Q46569157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

title

Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

6

H W Sollinger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

J Pascual

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

D Bloom

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

J Torrealba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

R Brahmbhatt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Z Chang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

language of work or name

English

0 references

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Transplantation

8 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

1529-1536

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Campath-1H in renal transplantation: The University of Wisconsin experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

A function for interleukin 2 in Foxp3-expressing regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2008.02260.X

10.1111/J.1600-6143.2008.02260.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18510645%20AND%20SRC:MED&resulttype=core&format=json

release_6vmr5j567jaablgofglwt6ayuy

8 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6vmr5j567jaablgofglwt6ayuy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference